The offering, which is set to close Tuesday, provides the Carlsbad-based company with a substantial runway to push forward its dabogratinib 3x3 development strategy. This initiative focuses on treating low-grade upper tract urothelial carcinoma, a specific area of oncological research that has become a core component of the firm's growth narrative. Beyond this clinical trial, the company plans to allocate the fresh capital toward its broader preclinical drug discovery efforts and general working capital requirements.

This latest move follows a period of intense market interest in the company, with stock value climbing 96% over the past twelve months. By combining the $400 million in proceeds with its existing cash reserves and marketable securities, Tyra is positioning itself to accelerate development timelines without immediate reliance on further external financing. The offering is entirely comprised of primary shares and warrants sold directly by the company, signaling a decisive effort to bolster its balance sheet while investor confidence remains high.